Kara Carter, PhD


Dr. Kara Carter is an Entrepreneur in Residence at Evotec focused on newco generation in the antiviral therapeutics space. Previously, she was EVP of Research at Dewpoint Therapeutics and was the founding head of the Sanofi virology therapeutic area, developing a portfolio of biologics and small molecule programs and leading the transition of that group from Sanofi to Evotec. Prior to that, she held positions of increasing responsibility at Genzyme leading small molecule discovery programs in oncology, renal biology, neurobiology, immunology, and rare disease.

In 2018, Dr. Carter was elected President of the International Society for Antiviral Research and currently serves as the Immediate Past President of the Society. She has been an active member of both the COVID R&D consortium and the ACTIV public private partnership responding to the COVID-19 pandemic and serves on the SABs of AD3C, an organization focused on the discovery and development of antivirals for pandemic potential agents, as well as READDi, an AViDD recipient based out of UNC.

Dr. Carter did her undergraduate studies at Stanford University, her doctoral work at the University of Chicago, and post-doctoral studies at Harvard University.